What to know about AMX0035 - a podcast by ALS TDI
from 2019-10-31T17:21:05
::
::
In this episode of the Endpoints, Dr. Steve Perrin, CSO at the ALS Therapy Development Institute, sits down to talk about AMX0035, a drug consisting of a combination of two small molecule compounds: sodium phenylbutyrate and tauroursodeoxycholic acid (TUDCA). Amylyx, the sponsor of AMX0035, recently completed enrollment of a 132 participant phase 2 trial.
To learn more about the ALS Therapy Development Institute and our mission to end ALS, click here.
Support the show: https://www.als.net/donate/
See omnystudio.com/listener for privacy information.
Further episodes of Endpoints
Further podcasts by ALS TDI
Website of ALS TDI